SwissMTB: establishing comprehensive molecular cancer diagnostics in Swiss clinics by Singer, Franziska et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2018
SwissMTB: establishing comprehensive molecular cancer diagnostics in Swiss
clinics
Singer, Franziska; Irmisch, Anja; Toussaint, Nora C; Grob, Linda; Singer, Jochen; Thurnherr, Thomas;
Beerenwinkel, Niko; Levesque, Mitchell P; Dummer, Reinhard; Quagliata, Luca; Rothschild, Sacha I;
Wicki, Andreas; Beisel, Christian; Stekhoven, Daniel J
Abstract: Background Molecular precision oncology is an emerging practice to improve cancer therapy
by decreasing the risk of choosing treatments that lack efficacy or cause adverse events. However, the
challenges of integrating molecular profiling into routine clinical care are manifold. From a computa-
tional perspective these include the importance of a short analysis turnaround time, the interpretation of
complex drug-gene and gene-gene interactions, and the necessity of standardized high-quality workflows.
In addition, difficulties faced when integrating molecular diagnostics into clinical practice are ethical con-
cerns, legal requirements, and limited availability of treatment options beyond standard of care as well
as the overall lack of awareness of their existence. Methods To the best of our knowledge, we are the first
group in Switzerland that established a workflow for personalized diagnostics based on comprehensive
high-throughput sequencing of tumors at the clinic. Our workflow, named SwissMTB (Swiss Molecular
Tumor Board), links genetic tumor alterations and gene expression to therapeutic options and clinical
trial opportunities. The resulting treatment recommendations are summarized in a clinical report and
discussed in a molecular tumor board at the clinic to support therapy decisions. Results Here we present
results from an observational pilot study including 22 late-stage cancer patients. In this study we were
able to identify actionable variants and corresponding therapies for 19 patients. Half of the patients were
analyzed retrospectively. In two patients we identified resistance-associated variants explaining lack of
therapy response. For five out of eleven patients analyzed before treatment the SwissMTB diagnostic
influenced treatment decision. Conclusions SwissMTB enables the analysis and clinical interpretation of
large numbers of potentially actionable molecular targets. Thus, our workflow paves the way towards a
more frequent use of comprehensive molecular diagnostics in Swiss hospitals.
DOI: https://doi.org/10.1186/s12911-018-0680-0
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-157621
Journal Article
Published Version
 
 
The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0)
License.
Originally published at:
Singer, Franziska; Irmisch, Anja; Toussaint, Nora C; Grob, Linda; Singer, Jochen; Thurnherr, Thomas;
Beerenwinkel, Niko; Levesque, Mitchell P; Dummer, Reinhard; Quagliata, Luca; Rothschild, Sacha I;
Wicki, Andreas; Beisel, Christian; Stekhoven, Daniel J (2018). SwissMTB: establishing comprehensive
molecular cancer diagnostics in Swiss clinics. BMC Medical Informatics and Decision Making, 18:89.
DOI: https://doi.org/10.1186/s12911-018-0680-0
2
RESEARCH ARTICLE Open Access
SwissMTB: establishing comprehensive
molecular cancer diagnostics in Swiss clinics
Franziska Singer1,2†, Anja Irmisch3†, Nora C. Toussaint1,2, Linda Grob1,2, Jochen Singer2,4, Thomas Thurnherr2,4,
Niko Beerenwinkel2,4, Mitchell P. Levesque3, Reinhard Dummer3, Luca Quagliata6, Sacha I. Rothschild5,
Andreas Wicki5, Christian Beisel4 and Daniel J. Stekhoven1,2*
Abstract
Background: Molecular precision oncology is an emerging practice to improve cancer therapy by decreasing the
risk of choosing treatments that lack efficacy or cause adverse events. However, the challenges of integrating
molecular profiling into routine clinical care are manifold. From a computational perspective these include the
importance of a short analysis turnaround time, the interpretation of complex drug-gene and gene-gene interactions,
and the necessity of standardized high-quality workflows. In addition, difficulties faced when integrating molecular
diagnostics into clinical practice are ethical concerns, legal requirements, and limited availability of treatment options
beyond standard of care as well as the overall lack of awareness of their existence.
Methods: To the best of our knowledge, we are the first group in Switzerland that established a workflow for
personalized diagnostics based on comprehensive high-throughput sequencing of tumors at the clinic. Our
workflow, named SwissMTB (Swiss Molecular Tumor Board), links genetic tumor alterations and gene expression
to therapeutic options and clinical trial opportunities. The resulting treatment recommendations are summarized
in a clinical report and discussed in a molecular tumor board at the clinic to support therapy decisions.
Results: Here we present results from an observational pilot study including 22 late-stage cancer patients. In this
study we were able to identify actionable variants and corresponding therapies for 19 patients. Half of the patients
were analyzed retrospectively. In two patients we identified resistance-associated variants explaining lack of therapy
response. For five out of eleven patients analyzed before treatment the SwissMTB diagnostic influenced treatment
decision.
Conclusions: SwissMTB enables the analysis and clinical interpretation of large numbers of potentially actionable
molecular targets. Thus, our workflow paves the way towards a more frequent use of comprehensive molecular
diagnostics in Swiss hospitals.
Keywords: Molecular diagnostics, NGS, Personalized medicine, Cancer diagnostics, Molecular tumor board
Background
In recent years, molecular profiling based on high-
throughput techniques has become an emerging practice
in hospitals all over the world [1]. Decreased sequencing
costs shifted the focus from traditional Sanger sequencing
of a few specific genomic loci [2] to gene panels targeting
a broader set of genes [3–5] and more comprehensive
approaches, including whole-exome sequencing (WES)
and whole-genome sequencing (WGS) [6, 7].
These emerging technologies hold great promise, in par-
ticular in regard to the identification of therapies for cancer
patients [8]. Cancer is one of the leading causes of death in
developed countries [9]. Despite decades of research the
mechanisms underlying carcinogenesis are not fully under-
stood and suitable treatment is not always available. Ther-
apies are typically active only in a limited number of
patients. Further, they are only successful for a short period
of time before the tumor develops resistance mechanisms
that lead to further disease progression [10–12]. Since
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tumors evolve via complex genetic changes [13], genomic
profiling of a tumor allows the prediction of targeted ther-
apies that are more likely to be active [6].
In recent years, an increasing number of molecular tar-
gets and corresponding drugs have been identified.
Prominent examples are BRAF mutations in metastatic
melanoma [14] and HER2 overexpression in breast cancer,
which can be targeted by specific kinase inhibitors or
monoclonal antibodies, e.g. vemurafenib and trastuzumab,
respectively [15, 16]. Consequently, the first molecular diag-
nostics initiatives using comprehensive next-generation se-
quencing (NGS) were launched 3–4 years ago [17], initially
mainly in the US (MD Anderson [18], Mayo Clinic [19],
Weill Cornell [20]), but recently also in Europe (DKFZ/
NCT [21]). In these initiatives, WES is used to comprehen-
sively analyze the protein-coding genes of the tumor gen-
ome. This allows us to detect not only cancer type specific
alterations, but also mutations common in other cancer
types, or mutations with associated therapies that are cur-
rently in clinical development. These efforts personalize
cancer treatment with a focus on suggesting therapy op-
tions for late-stage patients for whom standard treatment is
no longer effective. In this setting, reported success rates of
proposing therapies are at approximately 30% [19, 21].
When standard therapy options are also included (for in-
stance when applied as part of routine diagnostics), therapy
recommendations can be made for approximately 60% of
the patients [22]. At first glance, these numbers appear low;
however, there are multiple factors influencing the actual
success rate when using personalized molecular diagnostics.
First of all, it can be expected that with more known targets
these numbers will increase. In addition, one major hurdle
for precision medicine is drug access [19], as therapies be-
yond standard of care are often not available, i.e., not ap-
proved or not covered by health insurances, and access to
clinical trials is limited. Furthermore, currently comprehen-
sive molecular diagnostics is mainly applied to end-stage
cancer patients progressive on standard therapies. This
limits the number of therapies left for suggestion. Also,
rapid health deterioration or death is the main reason for
these patients not receiving molecular diagnostics-based
therapy. Finally, patient drop-out as well as limited aware-
ness of therapy options are a major issue impeding the
measurable success of molecular diagnostics [23].
In Swiss hospitals, targeted deep amplicon sequencing
mainly based on the Ion Torrent sequencing platform [24]
is currently the established standard for molecular diag-
nostics. In targeted sequencing, not the complete exome
but rather an a priori defined set of genes is analyzed in
order to reduce sequencing costs and analytical complex-
ity [3–5]. Gene panels need to be updated regularly to fol-
low the discovery of new targeted therapies. In the last 2
years, 20 new oncological therapies have been approved
by regulatory authorities in Switzerland [25]. However, by
design gene panels used in the clinic (e.g. the different Ion
Torrent Oncomine gene panels [26]) only include the
most common targetable genes matching approved ther-
apies. Thus, to identify therapy options beyond standard
of care more comprehensive sequencing technologies
such as WES or WGS may be beneficial.
Regardless of the sequencing technology, high-throughput
sequencing-based molecular diagnostics need a reliable
framework for annotation and clinical interpretation of
genetic variants [27, 28]. Currently, clinical interpretation
is mainly performed manually and thus very
time-consuming. Also, it is prone to miss very recent or
less well-known treatment options. In addition, available
databases for drug-gene interactions are either lacking the
level of manual curation necessary for reliable variant in-
terpretation [29–31] or are manually curated but cover
only a subset of available targets and therapies (e.g. the
current build of mycancergenome.org contains informa-
tion on 823 genes and 24 cancer types [32]). While the
major focus of molecular diagnostics is to propose a suit-
able therapy, the amount of time used to reach such a
proposition is of importance as well. For instance, patients
that showed progressive disease on all standard therapy
lines usually have only limited survival prospective.
Currently, the turnaround time of comprehensive molecu-
lar diagnostics workflows is typically about 3–12 weeks
[20, 33]. This needs to be reduced considerably in order to
make routine clinical application feasible, particularly for
end-of-treatment line patients.
Clinical interpretation has to be based on an accurate
picture of the genetic landscape of the tumor and its
origin. Thus, reliable variant calling is an important
part of each molecular profiling workflow. Benchmarks
on existing variant calling pipelines indicate that the
performance of variant detection methods can vary sig-
nificantly [34–36]. Each tumor presents a unique set of
genetic alterations that were involved in carcinogenesis.
Moreover, tumors do not evolve homogeneously, but as
subclonal populations. Each subclone has certain vari-
ants not shared with other clones of the same tumor,
which is challenging for the accurate variant identifica-
tion. As a result, choosing the right set of tools and pa-
rameters for a particular analysis is difficult. These
multifaceted challenges, which reach across different
fields of expertise, require an interdisciplinary approach
that combines different areas of knowledge and experi-
ence to advance the treatment of cancer patients [17,
28]. Clinical staff and bioinformaticians need to
collaborate to identify common criteria and goals to
enable a meaningful analysis and interpretation of gen-
etic variants. In addition, a definition of general rules
for data sharing between hospitals and computational
groups is required to enable a smooth and secure data
exchange.
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With the aforementioned challenges in mind, over the
last 2 years we combined the bioinformatics expertise of
the ETH technology platform NEXUS Personalized
Health Technologies (NEXUS) with the clinical expertise
of the University Hospitals in Zurich and Basel to design
and implement a workflow for molecular diagnostics of
cancer patients. We aimed at supporting treatment deci-
sions by comprehensively analyzing the genetic landscape
of tumors to link actionable genetic variants with therapy
recommendations. Tumor biopsies were collected at the
hospitals and then underwent high-throughput sequen-
cing by WES, WGS, RNA sequencing (RNA-seq), or gene
panels. The tumor samples were analyzed to identify tar-
getable genetic variants, which were further prioritized
based on their clinical significance. All findings were sum-
marized in a concise clinical report and discussed in a
multidisciplinary molecular tumor board with the goal to
recommend treatment options to the treating clinician.
Methods
As depicted in Fig. 1, SwissMTB is a collaborative effort
of clinicians and bioinformaticians. A tumor biopsy and
preferably a matched normal control sample (e.g., blood)
undergoes DNA and possibly RNA extraction, followed
by sequencing. Afterwards, the samples are analyzed
with regard to somatic alterations, i.e., genetic changes
that appear in the tumor, but not in the normal tissue. If
tumor RNA-seq data is available, gene expression levels
are determined and compared to a suitable reference co-
hort, e.g. TCGA Skin Cutaneous Melanoma [37], to
identify over- and underexpressed genes. Both genetic
and transcriptomic changes are then associated with
possible therapy options. Relevant therapies are summa-
rized in a clinical report that is discussed in an interdis-
ciplinary tumor board.
In our pilot study, we included patients from Univer-
sity Hospital Zurich and University Hospital Basel. In
Zurich, samples from stage IV melanoma patients pro-
gressive on standard therapy were analyzed using WES,
WGS, and, when feasible, RNA-seq. In Basel, samples of
various cancer types were analyzed using different Ion
Torrent amplicon panels. Our main objective is to iden-
tify targetable aberrations and to recommend new ther-
apy options for patients. Therefore, somatic variants
such as single nucleotide variants (SNVs), small inser-
tions and deletions (InDels), and copy number variants
(CNVs) were of particular interest. In addition, the over-
all mutational burden as an indicator of response to im-
munotherapy in melanoma [38] is determined based on
WES. Furthermore, WES enables inference of the pa-
tient’s HLA-I type as a treatment co-determining factor,
which is required for certain vaccination trials [39, 40].
RNA-seq is used to determine differentially expressed
genes as well as to validate targetable genomic variants,
in particular copy number changes.
A: Sample extraction and sequencing
Tumor tissue and, if possible, a normal control sample
(blood) of the patient are collected at the hospital. For the
SwissMTB pilot study fresh frozen samples (WES/WGS/
RNA-seq) as well as formalin-fixed paraffin embedded
(FFPE) samples (gene panels) were used. Integrated qual-
ity control steps ensure that genetic aberrations and po-
tential therapies are only inferred for samples and regions
passing previously defined quality thresholds.
DNA was extracted from the samples and prepared ac-
cording to the respective sequencing protocols. Panel se-
quencing was performed directly at the pathology
department of the University Hospital Basel. WES and
WGS sequencing were performed in external sequencing
facilities, either the Genomics Facility Basel or the Func-
tional Genomics Center Zurich. To save costs, in our pilot
study we performed a combined analysis of deep coverage
WES (approx. 120x-230x tumor coverage) for somatic
variant calling and low coverage (approx. 4x-13x tumor
coverage) WGS for CNV calling. For technical details such
as used panel type refer to Section “Results”.
B: Bioinformatics analysis
After sequencing, the resulting short DNA and RNA frag-
ments (called reads) were analyzed in order to identify
Fig. 1 SwissMTB molecular diagnostics workflow. DNA (and RNA) is extracted from a tumor biopsy (and paired control tissue, e.g., blood) and
sequenced. The resulting data is analyzed to detect genetic alterations (only in the tumor sample), which are associated with potential therapy
options. Suitable therapies and clinical trial options are summarized in a clinical report, which is returned to the clinician and discussed in the
molecular tumor board
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genomic and transcriptomic aberrations. In the following,
we briefly describe the bioinformatics analysis (Fig. 2).
DNA analysis
WES, WGS, and panel analysis mainly differ in their
pre-processing steps. The annotation and clinical inter-
pretation of variants is independent of the sequencing
type. First, the short DNA reads generated by the sequen-
cing machine are mapped to the human reference genome.
The resulting mapping is post-processed and used as the
basis for somatic variant (SNPs and InDels) and CNV call-
ing (based on WGS). The pipeline for WES/WGS analysis
from reads to unannotated variant calls is based on the
framework described in [41], employing the Snakemake
workflow environment [42]. Briefly, we follow the GATK
best practices for variant calling [43]. Instead of using a
single somatic variant caller we use a combination of three
callers, namely MuTect [44], VarScan2 [45], and Strelka
[46]. Only variants reported by at least two callers are con-
sidered, in order to identify variants with greater confi-
dence and to reduce the number of false positive calls. For
CNV calling on WGS data we use BIC-seq2 [47]. If WGS
is not available, we use EXCAVATOR [48] on WES data.
Variant calling on panel data depends on the sequencing
platform. For Ion Torrent data we rely on variants called
by Ion Reporter [26], the software suite accompanying Ion
Torrent. For Illumina data, we use the variant callers men-
tioned above, i.e., MuTect, VarScan2, and Strelka.
RNA analysis
If available, RNA-seq data is processed based on the
TCGA mRNA-seq Pipeline for UNC data [49], using
STAR [50] to align RNA reads to the human reference
genome. Typically, RNA-seq is only performed on tumor
tissue, since it is often infeasible to obtain an RNA sam-
ple extracted from corresponding normal tissue. In order
to determine if the expression of a gene is altered, we
compare it to the gene’s expression in the most appro-
priate publicly available reference cohort. In our pilot
study, we used either the TCGA Skin Cutaneous Melan-
oma [37] (SKCM) or the TCGA Uveal Melanoma [51]
(UVM) cohort. Normalized gene expression values for
those cohorts were downloaded from the Broad Institute
TCGA GDAC Firehose website [52]. Targetable genes
are considered for inclusion in the clinical report if they
are either over- or underexpressed. Furthermore, gene
expression is also used in the prioritization of genomic
variants. For instance, a gene deletion detected by WGS
or WES would be supported by RNA-seq if the observed
gene expression is low or the gene is not expressed at all.
Annotation and prioritization
The number of observed somatic variants differs greatly
depending on the tumor type [53]. However, the number
of potentially interesting variants for a patient is usually
too large to be processed manually, particularly within
the desired short time-frame for generating a clinical re-
port. Thus, the identified variants are annotated with in-
formation from databases such as COSMIC [54], dbSNP
[55, 56], and ClinVar [57]. Additionally, we query cBio-
Portal [58, 59] to inform on the incidence of each variant
across cancer types. Further, we annotate overall muta-
tion type (e.g., missense or nonsense mutation, splice
site mutation etc.), likely functional impact, and associ-
ated pathways. These types of information help to
prioritize variants with respect to their significance for
Fig. 2 Overview of the SwissMTB bioinformatics analysis workflow. The reads generated by the sequencer are first mapped to the human reference
genome. Afterwards, somatic variant and copy number variant calling is performed. Variants are annotated and then prioritized according to clinical
relevance. RNA-seq based gene expression levels are compared to publicly available tumor sample cohorts. The findings are summarized in a clinical
report. All steps from mapping to prioritization are fully automatized using a Snakemake-based pipeline. Selecting variants and therapies for the report
is currently mainly manual work. All steps are documented and quality controlled, partly based on built-in routines in the analysis pipelines
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tumor development or treatment resistance. For instance,
in colorectal cancer new mutations in the MAPK signaling
pathway can confer resistance against combined RAF/
MEK therapy by sustaining the activity of the pathway [60].
Furthermore, we query DGIdb [29, 61, 62] to get the
drug-gene interactions reported in a collection of 30 da-
tabases, of which several are expert-curated (e.g. MyCan-
cerGenome [63]). The more databases support an
interaction, the higher the priority of the drug. In
addition, we query all possible drugs at Swissmedic [25],
the Swiss regulatory authority for drugs and medical
products. Of highest priority are drugs that are available
in Switzerland. Finally, based on drug-gene interactions
identified in DGIdb we collect associated clinical trials at
ClinicalTrials.gov. Clinical trials are important in two
regards: First, completed trials inform on the suitability
of a therapy and its confidence level in the report. Sec-
ond, open clinical trials make therapies available to the
patient, if the patient is eligible for the trial. Trials that
explicitly require the observed variant for therapy eligi-
bility are of particular interest.
The combination of the aforementioned information is
essential for the generation of a clinical report reliably
summarizing all relevant therapies for the treating clin-
ician. Until this point, all steps are automated, and de-
pending on sequencing depth the bioinformatics analyses
takes approximately six hours. The main bottleneck re-
garding turnaround time is the manual generation of the
clinical report, which is described in the following section.
C: Clinical report
The clinical report is a concise summary of relevant
therapies identified based on the genetic and transcrip-
tomic landscape of the tumor. It is the basis for discus-
sion in a molecular tumor board and informs on therapy
options arising from the molecular alterations present in
the tumor. Each recommended therapy is associated
with an identified variant, and the relevance and reliabil-
ity of each therapy is assessed based on evidence in the
literature, such as previous preclinical studies and clin-
ical trials. The clinical report is intended to only present
the relevant subset of variants found in a tumor. This
subset is derived based on the knowledge at the time of
analysis and is thus likely to change over time, for in-
stance if new targets are identified or therapies become
Swissmedic approved. Therefore, each report is accom-
panied by an addendum listing all identified aberrations.
The clinical report is structured such that the results
are communicated to the tumor board as purposeful as
possible [64]. It has an overview page, presenting the
most important information regarding therapy recom-
mendations, accompanied by various sections with rele-
vant details (Additional file 1).
The overview page (Fig. 3) contains basic data on the
patient, the tumor sample, and the treating clinician. It
further summarizes the proposed therapy options, and
presents results on mutational burden and HLA-I type.
In addition, it gives an overview of the mutational status
of genes frequently described as mutated in the given
cancer, to allow the clinician to easily assess whether
important genes are mutated or not. For instance, the
status of BRAF in melanoma (mutations prevalent in
40–50% of all cases [14]) or ALK in lung cancer
(rearrangements prevalent in 4–5% of all non-small cell
lung cancers [65]) influences eligibility for clinical trials.
The list of important genes is derived either by personal
communication with the responsible clinician or based
on MyCancerGenome [63] and relevant literature.
In addition to therapy recommendations, also indicat-
ing possible drug resistances is of interest. For instance,
various TP53 mutations have been reported to confer re-
sistance to platinum-based chemotherapy in ovarian
cancer [66]. Such findings are reported in a separate sec-
tion (entitled “Therapies potentially lacking benefit”) and
are also highlighted on the overview page. In our ex-
ample, the low mutational burden indicates only limited
benefit of Anti-CTLA4 therapy (Fig. 4) [38].
We categorize findings into different levels of confi-
dence that are used to assess the relevance of the poten-
tial therapy. For categorization, we follow the guidelines
in [67] (refer to Fig. 5 for the confidence level overview).
Recommended drugs that are Swissmedic approved
have the highest confidence level (level A), followed by
those that have proven successful for treatment in sev-
eral well-powered clinical studies (preferably phase 3).
Drug targets that are Swissmedic approved for a differ-
ent type of cancer or have been tested in smaller studies
for the cancer type at hand have lesser confidence (level
C). Finally, targets that have only been tested in preclin-
ical studies are in the lowest confidence category (level
D). This way the applicability of a recommended therapy
can be assessed easily. In addition, we list the literature
support for each included drug-gene interaction to allow
a detailed assessment of the reasons why this particular
therapy is recommended.
In the report, therapies are grouped into different sec-
tions (Fig. 6), namely “cancer type specific therapies”
(Swissmedic approved for the given indication), “non
cancer type specific therapies” (Swissmedic approved for a
different indication), and “investigational therapies” (not
Swissmedic approved). The different sections contain the
most relevant information for each recommendation: gene
and drug name, observed variant, variant frequency or
copy number, associated pathway, variant effect (if known,
for instance gain-of-function or loss-of-function as indi-
cated in OncoKB [68]), confidence level, and literature
support. Further, as exemplified in Fig. 6, the relative gene
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Fig. 3 The overview page of an example clinical report including the categorization of therapies into cancer type specific, off-label (non cancer
type specific), investigational, and possibly contraindicated therapies. We indicate the mutation status of commonly mutated genes, visualize the
mutational burden of the patient, and inform on the patient’s HLA type
Fig. 4 Report section for therapies potentially lacking benefit. Gene name and variant type, as well as observed frequency, copy number, or gene
expression are presented to indicate resistance-causing events. Furthermore, details on the affected therapy, as well as a brief description of the
finding and literature support are provided
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Fig. 5 Therapy recommendation confidence levels, based on categorization by the Association for Molecular Pathology, American Society of
Clinical Oncology, and College of American Pathologists [67]
Fig. 6 Example for therapy categories for a melanoma patient presenting (among other mutations) several copy number mutations, an FGFR4
overexpression, and a BRAF V600E point mutation, identified based on WES, WGS, and RNA-seq data. Each table is structured as follows: Column
“Gene” shows the name of the affected gene. Column “Variant” either contains the exact amino acid change resulting from a point mutation, or
states the copy number change (amplification or deletion), or presents the change observed by the RNA-seq analysis (e.g. overexpression).
Column “Frequency or Copy number” presents the variant frequency of point mutations (in percent), or presents the copy number observed for
the affected gene. Column “Relative gene expression” includes the boxplot that shows the expression of the particular gene in comparison to the
TCGA cohort of the same cancer type. For ease of interpretation, the different types of boxplot are explained in the “Guide section” of the clinical
report, Additional file 1. Column “Pathway/Function” gives details on the functions of a gene. Column “Therapy” shows the name of the drug
with a potential drug-gene interaction, while columns “Confidence” and “References” present the confidence level and the literature support of
the drug-gene interaction, respectively
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expression of the mutated gene in comparison to the
TCGA cohort of the same cancer type is shown in a separ-
ate column (the gene expression plots are explained in the
report glossary, Additional file 1).
Finally, not only therapies are recommended to the
treating clinician, but also potentially relevant open clin-
ical trials (refer to Fig. 7 for an example table). We prefer
trials of higher phase and located in or near Switzerland,
and give a brief overview of each trial by including study
title, trial phase, and location. Ultimately, suitability of a
trial has to be decided by the clinician, because we do not
have access to all information necessary to assess a pa-
tient’s eligibility.
The BRAF mutation observed in our example patient
illustrates how the clinical report can be utilized to fa-
cilitate clinical decision making. BRAF V600E is a
well-known therapy target in melanoma and thus
assigned the highest confidence. As shown in Fig. 6 in
the green table, Swissmedic approved therapies are avail-
able (dabrafenib and vemurafenib). However, also inves-
tigational therapies targeting BRAF are possible, namely
LTT462 and LXH254. Both compounds are not yet
Swissmedic approved and have only been tested in a few
studies, but they might become relevant therapy options
if the patient has already received (and progressed on)
other therapies. As shown in Fig. 7, for both LTT462
and LXH452 clinical trials are recruiting in Switzerland,
such that the compounds might indeed be accessible to
the patient. This example shows the tight link between
the different sections of the clinical report: at first glance
investigational therapies might seem rather irrelevant
and hardly accessible, but the clinical trials section dir-
ectly shows whether the drug might nevertheless be
available. It also highlights the advantages of compre-
hensive sequencing: only focusing on well-known targets
cannot provide information on newer and less known
therapy targets. Since tumors often become resistant to
the applied therapies, pointing out alternatives that
might work on these resistant tumors may be important
for pre-treated patients.
Results
Up to now, 22 patients progressive on standard treat-
ments have been included in the SwissMTB study. From
the dermatology department at the University Hospital
Zurich we prospectively analyzed eleven patients with
metastatic cutaneous, uveal, and mucosal melanoma
(Table 1). These patients were sequenced based on WES
accompanied by WGS (except for the first patient for
whom only WES was performed). For five of the most
recent patients we also performed RNA-seq to identify
transcriptomic aberrations. In three of these patients,
gene expression results affected therapy recommenda-
tions. From the University Hospital Basel, we analyzed
eleven patients with various cancer types (Table 2).
These samples were analyzed in retrospect, after the ac-
tual therapy had been applied.
The SwissMTB analyses for the University Hospital
Zurich were performed before treatment. Thus, for some
patients the molecular findings could influence treatment
Fig. 7 Example for clinical trial options presented in a clinical report
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decisions. Unfortunately, similar as in other molecular
tumor board approaches (e.g. [19, 69]), half of the patients
experienced rapid health deterioration, such that for only
six patients SwissMTB treatment recommendations could
be discussed in the molecular tumor board. Namely, from
the eleven patients presented in Table 1, patients 1, 6, 7, 9,
and 10 died or were too far declined in health before the
findings could be presented to the clinicians. Results from
the six remaining patients have been discussed, and for
five patients, namely patients 2, 4, 5, 8, and 11, the
SwissMTB findings indeed influenced the treatment
decision.
To be more specific, for patient 2 (refer to Table 1) the
WES analysis showed that the sequenced tumor material
had a very high mutational load with 826 non-synonymous
protein-coding mutations. A high mutational load above
100 non-synonymous coding mutations has been shown to
be predictive of positive response to ipilimumab therapy in
melanoma [38]. Based on this finding and the recent ap-
proval of the combined checkpoint blockade of
anti-CTLA4 and anti-PD1 therapy that results in higher re-
sponse rates than single anti-CTLA4 treatment [70], com-
bination treatment with ipilimumab and nivolumab was
started. The patient experienced complete tumor regres-
sion after 2 months and continued on immunotherapy
treatment, where he stayed tumor-free for 8 months.
Furthermore, the patient’s tumor harbored amplifications
of BRAF, EGFR, MET, and CDK6, which provides a
rationale for this tumor’s acquired resistance to the triple
BRAF/MEK/CDK4&6 inhibitor treatment applied before
sequencing [71, 72].
For patient 3 (Table 1) the results showed an NRAS
Q61K activation resistance variant, which leads to reacti-
vation of the MAPK pathway in the presence of BRAF
inhibitors. Trametinib, which inhibits the downstream
MEK kinase, was therefore suggested as a matching drug
on the report. However, it is known that the in vitro re-
sponse of double NRAS and BRAF mutated cells to
MEK inhibitors is heterogeneous [73]. The tumor board
therefore decided on the newly approved combination
Table 1 Overview of patients analyzed based on comprehensive sequencing
Patient Cancer Type Sequen-cing No. of
actionable
variants
No. of therapies
(cancer-type specific,
off-label, investigational)
No. of therapies
lacking benefit
Comments
1 Cutaneous
Melanoma
WES 13 12 (2,4,6) NA (not yet
part of
workflow)
Patient died before the report could be delivered.
Based on an observed PTCH1 amplification reported in
the SwissMTB analysis, vismodegib would have been
considered as treatment.
2 Cutaneous
Melanoma
WES 13 19 (2,12,5) 5 Based on the high mutational load of this tumor
anti-CTLA4 treatment was recommended. The patient
was treated accordingly and showed a complete response.
3 Cutaneous
Melanoma
WES/WGS 6 12 (3,4,5) 5 NRAS Q61K resistance variant identified and trametinib
treatment recommended.
4 Uveal
Melanoma
WES/WGS 3 7 (0,4,3) 5 Based on a PXR loss Taxol treatment was recommended.
The patient was treated accordingly, but progressed
after 2 months of therapy.
5 Cutaneous
Melanoma
WES/WGS 5 8 (2,5,1) 3 Based on the high mutational load anti-CTLA4 treatment
was recommended. The patient was treated accordingly
with a combination of anti-CTLA4 and anti-PD1 therapy
and showed partial response.
6 Mucosal
Melanoma
WES/WGS/
RNA-seq
3 7 (0,4,3) 3 At the time of report delivery, the condition of the patient
did not allow any treatment.
7 Mucosal
Melanoma
WES/WGS/
RNA-seq
6 12 (0,7,5) 1 Patient died before the report could be delivered.
8 Uveal
Melanoma
WES/WGS 4 10 (0,4,6) 1 Based on GNA11 Q209L variant treatment with sorafenib
was decided but insurance did not cover drug costs.
9 Uveal
Melanoma
WES/WGS/
RNA-seq
4 10 (0,4,6) 1 Patient died before the report could be delivered.
10 Uveal
Melanoma
WES/WGS/
RNA-seq
5 11 (0,5,6) 1 Based on observed FGFR4 overexpression, ponatinib was
recommended as off-label treatment. However, the
patient died before the report could be discussed in
the molecular tumor board.
11 Cutaneous
Melanoma
WES/WGS/
RNA-Seq
4 6 (0,4,2) 0 Based on observed MET overexpression the patient
received crizotinib as off-label treatment.
Summary: median (IQR) 5 (2) 10 (4.5) 2 (3.5)
Abbreviations: IQR Interquartile range
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therapy of the checkpoint inhibitors ipilimumab with
nivolumab. The patient progressed on this therapy, which
is in concordance with the low mutation rate reported by
WES analysis and the associated contraindication of im-
munotherapy indicated in the report. At the time of
manuscript submission, it was not yet decided whether
the therapy will be switched to the alternatively proposed
drug trametinib.
For patient 4 (refer to Table 1), who has a rare uveal
melanoma, we reported the loss of the pregnane X recep-
tor (PXR) as an actionable variant. This receptor binds
chemotherapy agents such as taxanes and regulates drug
metabolizing enzymes. PXR knockdown in cancer cells in-
duces increased paclitaxel sensitivity and apoptotic cell
death [74]. Also, in uveal melanoma paclitaxel treatment
is known to induce stable disease in one third of patients
[75]. The tumor board therefore decided to initiate treat-
ment with paclitaxel. However, the patient progressed
with new metastases after 2 months of treatment.
For patient 5 (Table 1) the report indicated a high muta-
tional load. Therefore, the patient was treated with com-
bined immune checkpoint blockade, which resulted in a
partial response with most metastases regressing.
In patient 6 an amplification of the Src kinase LYN
was detected in the WGS analysis. This indicates benefit
of the LYN kinase inhibitors masitinib and bosutinib,
which have been shown to be effective in cancer therapy
[76, 77]. However, RNA-seq analysis showed that LYN
Table 2 Overview of patients analyzed based on panel data, only tumor samples were sequenced
Patient Cancer Type Panel type No. of
actionable
variants
No. of therapies
(cancer-type specific,
off-label, investigational)
No. of therapies
lacking benefit
Comments
12 Fibroblastic
osteosarcoma
Oncomine
Comprehensive
Panel
0 0 0 Only germline variants detected in sample.
13 Head and Neck
Squamous cell
carcinoma
Cancer HotSpot
Panel 2.0
12 12 (6,6,0) 0 Various damaging variants in genes of MAPK
signaling pathway detected. Tyrosine kinase
inhibitor treatment recommended.
14 Lung
neuroendocrine
carcinoma
Cancer HotSpot
Panel 2.0
1 1 (0,1,0) 0 Based on FBXW7 D440Y variant mTOR inhibitor
treatment recommended.
15 Ovarian serous
carcinoma
Cancer HotSpot
Panel 2.0
1 1 (1,0,0) 1 Based on observed TP53 V173 L resistance
variant doxorubicin treatment recommended
and platinum-based treatment discouraged.
As indicated in SwissMTB analysis, progressive
disease under carboplatin treatment.
16 Cutaneous
melanoma
Cancer HotSpot
Panel 2.0
2 3 (2,1,0) 0 Based on CDKN2A R80* loss-of-function variant
off-label treatment with palbociclib recommended.
17 Chondrosarcoma Oncomine Solid
Tumor DNA
Panel
10 9 (0,9,0) 3 Tyrosine kinase inhibitor treatment recommended.
Patient was treated with pazopanib, response
status unknown.
Four resistance-associated variants found: ALK
G1202R, KRAS S65 N, TP53 C275Y, and TP53 G245D.
18 Lung
adenocarcinoma
Liquid Biopsy,
Oncomine
Solid Tumor
DNA Panel
0 0 0 No tumor DNA contained in sample.
19 Lung
adenocarcinoma
Liquid Biopsy,
Oncomine
Solid Tumor
DNA Panel
1 0 1 Use of ALK inhibitors discouraged because of
ALK G1202R resistance variant.
As indicated in SwissMTB analysis, progressive
disease under crizotinib treatment.
20 Lung squamous
cell carcinoma
Oncomine
Solid Tumor
DNA Panel
1 1 (1,0,0) 1 Paclitaxel recommended based on observed
TP53 R342* variant.Contradictive case, as a
second TP53 R248Q variant is associated with
increased chemotherapy resistance.
21 Neuroectodermal
sarcoma
Cancer HotSpot
Panel 2.0
0 0 0 No variants identified.
22 Cutaneous
melanoma
Cancer HotSpot
Panel 2.0
5 11 (1,9,1) 1 Multi-kinase inhibitor treatment recommended,
cisplatin treatment discouraged based on TP53
R273S resistance variant.
Summary: median (IQR) 1 (3) 1 (6) 0 (1)
Note that the SwissMTB analysis of these samples was performed retrospectively. Abbreviations: IQR Interquartile range
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expression is comparatively low with respect to the
TCGA SKCM cohort [37]. Therefore, therapy with bosu-
tinib and masitinib would likely have lacked benefit in
this patient. This finding was included in the report.
However, at the time of report delivery, the condition of
the patient did not allow any treatment.
Based on the variant GNA11 Q209L identified in the
uveal melanoma of patient 8 off-label treatment with so-
rafenib was decided by the tumor board. However, the
insurance did not cover the therapy costs. Up to the
time of manuscript submission no alternative treatment
decision has been made.
For patient 10 FGFR4 overexpression was determined
by comparing the patient’s gene expression to the TCGA
UVM cohort [51]. Ponatinib and other pan-FGFR inhibi-
tors are currently being investigated in clinical trials to
determine their potential in treating FGFR aberrant can-
cers [78]. These treatments were included in the report.
However, patient 10 died before report delivery, and thus
these findings were not discussed in the tumor board.
For patient 11 we reported a significant MET overex-
pression with respect to the TCGA SKCM [37] cohort.
In a recent study, Yang et al. [79] reported tumor shrink-
age and clinical benefit in gastric cancer patients with
MET overexpression on crizotinib treatment. Based on
these findings, off-label treatment with crizotinib was
started. Unfortunately, the patient progressed on this
treatment and died after a few weeks.
In Basel, the SwissMTB workflow was applied retro-
spectively to samples of patients who had already been
treated. Thus, the SwissMTB findings did not influence
treatment decision, but we can compare recommended
and discouraged therapies with the actual therapy
choice. Table 2 summarizes the results of the SwissMTB
analysis for the panel-based analysis of patients 12 to 22.
Since patients 12, 18, and 21 presented no actionable
variants we did not recommend any therapies. For all of
the remaining eight patients we found variants with pos-
sible treatment relevance. Only patient 20 presented in-
conclusive results that would need further investigation.
In four of the patients, namely patients 15, 17, 19, and
22, resistance mutations were identified. Notably, in two
of these cases (patients 15 and 19) the patients had re-
ceived therapies for which we found resistance muta-
tions, and indeed the clinical follow-up showed lack of
response to these therapies.
For patient 13 several damaging variants were identi-
fied in genes associated with the MAPK signaling path-
way. Thus, in the report use of tyrosine kinase inhibitors
was recommended, e.g. pazopanib or lenvatinib. How-
ever, at the time of treatment decision information on
these molecular targets was not available to the clinician,
and thus a targeted therapy was not considered. The pa-
tient instead received and progressed on three lines of
therapy including carboplatin+paclitaxel chemotherapy
and immunotherapy with nivolumab.
For patient 14 the SwissMTB molecular diagnostic identi-
fied a variant in the WD40 domain of the tumor suppressor
gene FBXW7. We recommended mTOR inhibitor treat-
ment, for instance with everolimus [80]. Mixed responses
to this treatment have been reported in the literature [81].
However, low response was shown in particular in the pres-
ence of other simultaneous variants, for instance in KRAS.
Since in the panel-based analysis the observed FBXW7
variant appeared as the only mutation, a therapy with
mTOR inhibitors such as everolimus might be justified. For
this patient no clinical follow-up data was available.
Patient 15, who had ovarian cancer, showed a TP53
V173 L mutation that is associated with a higher likeli-
hood of platinum treatment resistance [66, 82]. The pa-
tient received the platinum-based chemotherapy
carboplatin, and indeed the therapy lacked efficacy. In the
SwissMTB report we instead recommended doxorubicin
treatment, which was reported to be effective in in the
presence of platinum resistance [83, 84].
Patient 16 received anti-CTLA4 immunotherapy, which
resulted in a stable disease. In case of disease progression
the SwissMTB report recommends off-label treatment
with palbociclib to target the observed loss-of-function
variant R80* in CDKN2A [85, 86].
Patient 17 presented four different resistance muta-
tions, namely ALK G1202R, KRAS S65 N, TP53 C275Y,
and TP53 G245D. Thus, in the SwissMTB report we dis-
couraged the use of ALK inhibitors, cetuximab, and cis-
platin treatment. Instead, we recommended treatment
with tyrosine kinase and mTOR inhibitors such as pazo-
panib and everolimus based on several variants in genes
associated to the MAPK signaling pathway and mTOR
signaling pathway. The patient was treated with pazopa-
nib; however, at the time of writing no information on
treatment response was available.
Patient 19 presented a lung adenocarcinoma with an
ALK G1202R variant, a mutation associated with general
resistance against ALK inhibition [87–89]. As predicted
based on the observed variant, the patient showed a pro-
gressive disease when treated with the ALK kinase in-
hibitor crizotinib.
The SwissMTB analysis of the lung squamous cell car-
cinoma of patient 20 presents an example of inconclu-
sive results. Here, the only two identified variants were
TP53 R342* and TP53 R248Q. Contradicting results are
reported regarding the sensitivity or resistance to pacli-
taxel treatment in the presence of these variants [90, 91].
Thus, paclitaxel is indicated in the clinical report as pos-
sible therapy option that needs further investigation.
For patient 22 we identified TP53 R273S, a variant as-
sociated to cisplatin therapy resistance in a variety of
cancer types [82, 92]. The patient showed a progressive
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disease under anti-CTLA4 and anti-PD1 immunother-
apy. According to the SwissMTB molecular diagnostic
other therapy options would have been off-label tyrosine
kinase inhibition, e.g. with sunitinib or regorafenib,
based on multiple variants in the MAPK signaling path-
way and a KIT exon11 variant [93, 94].
Discussion
The conducted pilot project only comprises a small
number of patients and can thus only serve as a
proof-of-concept to show the feasibility of the
SwissMTB workflow in a clinical setting. Larger clinical
trials including a control group are required to deter-
mine whether approaches based on comprehensive mo-
lecular tumor analysis offer significant clinical benefit to
late stage cancer patients. Nonetheless, single patients
showed clinical benefit from our SwissMTB approach.
In summary, we were able to recommend therapies for
19 out of 22 patients (86%), which exceeds the recommen-
dation success rate of 60% generally reported in the litera-
ture [22]. As clinicians were directly involved in the
SwissMTB workflow, our study did not suffer from limita-
tions such as lack of awareness of available therapies.
Thus, when the influence of factors like limited awareness
of therapeutic options and patient drop-out is reduced,
the actual benefit of molecular diagnostics might be
higher than visible from numbers reported in the litera-
ture. For five out of eleven patients analyzed before treat-
ment, the SwissMTB diagnostics influenced the treatment
decision. Four of them received the recommended therapy
(in one case the insurance did not cover the treatment
costs), and two of these patients responded well. In
addition, we identified clinically relevant variants in eight
of eleven cases in the retrospective analysis based on
panels. For six of these patients, SwissMTB proposed
promising actionable targets and possible targeted treat-
ments. Since most patients included in the pilot cohort
progressed on their received standard therapy, these find-
ings would have been relevant treatment alternatives or
follow-up treatment options. Importantly, we also identi-
fied resistance variants for treatments that indeed proved
ineffective in the clinical follow-up. Thus, for two patients
analysed retrospectively, our analysis likely would have
prevented a non-beneficial therapy. Overall, the results of
this pilot cohort, despite being small and preliminary, in-
dicate the benefit of the SwissMTB workflow. Further, the
pilot study suggests an added value of integrating
RNA-seq information, as gene expression results affected
therapy recommendations in three out of the five cases
with available RNA.
In Switzerland, SwissMTB is the first workflow for a
molecular tumor board based on comprehensive sequen-
cing techniques like WES, WGS, and RNA-seq. Other
initiatives, e.g. at the Weill Cornell Cancer Center in
New York [20], or at the DKFZ in Heidelberg [21], also
implement comprehensive molecular diagnostics, al-
though typically they are based on WES only [19, 20].
Only few cohort studies published so far include
RNAseq-based analysis for direct treatment prediction
[95, 96]. Importantly, since Swiss regulations differ from
regulations in other countries, e.g. the US or Germany,
molecular tumor board workflows from other countries
cannot be applied straightforwardly in Switzerland. In
contrast, SwissMTB was specifically designed to be used
in Swiss clinical practice, and thus it adheres to the
guidelines of the Swiss authorities.
Already today, many hospitals have implemented mo-
lecular tumor boards to discuss treatment decisions.
However, these tumor boards almost exclusively look at
NGS results from gene panel sequencing. In contrast,
SwissMTB targets not only a limited set of genes, but of-
fers a comprehensive view on the genomic and, add-
itionally, transcriptional landscape of the tumor. Thus, it
goes beyond the workflows currently implemented in
the hospitals. Reasons why in Swiss hospitals gene panels
are the de facto standard for NGS-based analyses are
mostly the lower sequencing costs and straightforward
variant interpretation. However, WES and WGS are
more comprehensive and can provide a clearer picture
of the mutational landscape of the tumor. For instance,
important features such as the HLA type cannot be
assessed with commonly used panels, but only with
more comprehensive approaches. Similarly, tumor muta-
tional burden, an important predictor of immune check-
point therapy response, cannot be analyzed by most
smaller routine panels. Routine diagnostics often lack
the computational methods to filter and prioritize the
often large number of variants identified in WES/WGS.
Since SwissMTB provides the means to analyze and per-
form drug-matching of a large numbers of variants, our
workflow paves the way towards a more frequent use of
comprehensive molecular diagnostics in Swiss hospitals.
Another advantage of SwissMTB is its support of the
simultaneous analysis of tumor and matched control
samples. In Swiss hospitals NGS-based diagnostics is al-
most exclusively performed on tumor-only samples.
However, we strongly encourage the use of a matched
normal sample in order to directly call somatic aberra-
tions and to decrease the risk of identifying germline
variants. Recently, a study by Sun et al. [97] showed that
clinically reliably somatic variant calling is also possible
without a matched normal. However, the approach has
various constraints such as requiring high sequencing
depths of more than 500x, and thus is currently infeas-
ible for WES and WGS in clinical practice. However,
particularly for WES and WGS sequencing the number
of germline variants would impede the search for
tumor-relevant variants. Furthermore, investigating
Singer et al. BMC Medical Informatics and Decision Making           (2018) 18:89 Page 12 of 18
germline variants of a patient requires special ethical con-
sideration. For panel sequencing the use of a matched
normal control is advisable for the same reason. However,
it is not yet common practice – and sometimes not even
possible – to obtain such a sample. In our study, a
matched normal sample was used for WES and WGS. In
contrast, both panel-based analysis and RNA-seq were ex-
clusively performed on tumor samples. As discussed
below, this led to germline variant identification in one of
the patients.
When we compare the overall results of the analysis
based on comprehensive sequencing versus panel sequen-
cing, we see that with panels generally less actionable vari-
ants are found, resulting in less therapy options and less
insight into drug resistance and clinical trials. This effect
can be observed independently of the panel type used, and
further underlines the benefit of using comprehensive se-
quencing instead of targeted panels. Notably, the patients
from University Hospital Basel presented various cancer
types. Thus, compared to melanoma there might be less
actionable variants and therapies available. For better
comparability we only considered the patients with melan-
oma (two patients) or lung cancer (four patients) for a less
biased second comparison. However, even on this limited
number of patients overall less actionable variants and
corresponding treatments were identified, namely a me-
dian number of one variant and one therapy, including
standard therapies.
Notably, the patients from our cohort had already re-
ceived a number of therapies before they entered our
study. Even when excluding these therapies, still off-label
and investigational therapies were recommended for all
eleven patients analyzed with WES/WGS, and only for six
patients analyzed based on panels. Each report based on
comprehensive sequencing proposes a median number of
ten such therapies linked to a median number of six trials
per patient. Note that this number already represents a se-
lected set of preferable trials (e.g. trials conducted in or
near Switzerland, if those were available).
In the panel-based analysis, we identified actionable
variants in eight of the eleven patients. For these eight
patients, a median of two therapies was recommended
per patient with a median of one off-label or investiga-
tional therapy linked to a median number of 2.5 clinical
trials. There are several possible reasons for the lack of
actionable variants in three of the eleven patients. In
case of patient 18 (refer to Table 2) the amount of tumor
DNA in the sample was not sufficient. This sample was
taken by liquid biopsy, a technique that extracts cell-free
circulating tumor DNA from the blood. Here, wild-type
DNA is much more abundant than tumor DNA. Thus,
the sequencing and bioinformatics analysis of liquid bi-
opsy samples is even more challenging compared to
tumor biopsy samples [98]. For patients 12 and 21
(Table 2) no variants could be identified, except for
germline variants in patient 12. On the one hand, this
shows the importance of a normal control sample to de-
crease the risk of identifying germline variants. On the
other hand, both patient 12 and 21 presented rare tumor
types (fibroblastic osteosarcoma and neuroectodermal
sarcoma, respectively) for which few therapy targets are
known. Patients with such rare tumor types might bene-
fit from an analysis based on comprehensive WES/WGS,
since panels might not contain the required targets.
In general, it would be advantageous to perform mo-
lecular diagnostics directly at the entry point in the clinic.
This is particularly true for panel-based analyses. Patients
at later stages that already received a number of standard
therapies might need off-label and investigational therapy
recommendations. The gene panel might not cover the
relevant therapy targets and thus could fail to inform on
additional therapy options, as can be observed in our
study where for only six of the patients analyzed based on
panels therapies beyond standard of care could be identi-
fied. However, Table 1 shows that also molecular diagnos-
tics based on comprehensive sequencing would benefit
from an earlier time of sequencing. To speed up the report
delivery, we implemented a two-step procedure. A
so-called level-1 report that includes unfiltered actionable
variants and corresponding treatments is generated auto-
matically without manual inspection. Thus, it is delivered
to the clinicians and oncologists within one day after the
sequencing has finished. The level-2 report, namely the
clinical report including the filtered and manually
inspected variants and treatments, is reported after ap-
proximately 4 weeks. However, even with this two-step
procedure five of the ten dermatology patients died or
presented a too severe health condition to allow starting
new therapies before the report could be delivered. This
stresses the importance of decreasing the analysis turn-
around time. It also shows that patients can benefit most
from molecular diagnostics if tumors are sequenced at
diagnosis or before entering the last standard treatment
line.
Conclusions
In conclusion, molecular profiling based on high-throughput
technologies is an emerging practice in hospitals all over
the world that allows for the detection of genomic aberra-
tions involved in carcinogenesis and therapy resistance.
To the best of our knowledge, we introduced the first
comprehensive high-throughput sequencing based mo-
lecular profiling workflow in Swiss clinics. In a collabor-
ation of the NEXUS Clinical Bioinformatics Unit of ETH
Zurich and the University Hospitals Zurich and Basel a
workflow for tumor sample extraction, bioinformatics
analysis, and clinical reporting has been implemented and
tested in a pilot project involving 22 patients. We
Singer et al. BMC Medical Informatics and Decision Making           (2018) 18:89 Page 13 of 18
identified actionable targets in 86% of the patients, and in
addition identified several resistance-causing variants. In five
of eleven patients sequenced before treatment, SwissMTB
findings influenced treatment decisions, which demonstrates
the benefit of comprehensive sequencing based molecular
diagnostics. We have shown that the close collaboration of
clinicians and bioinformaticians enables the identification of
new therapy options for end-of-treatment line patients. The
wealth of information accessible with comprehensive
high-throughput sequencing requires sophisticated analysis
workflows, but allows for generating novel treatment
suggestions. Thus, already today traditional Sanger
sequencing-based diagnostic methods are being replaced by
high-throughput NGS-based techniques.
Once decreasing sequencing costs will make reim-
bursement from Swiss health insurances for WES and
WGS feasible, these methods likely will become standard
diagnostic tools, not only for patients that have pro-
gressed on standard therapies but for every cancer pa-
tient entering the clinic. Our molecular diagnostics
workflow provides a prototype that can form the basis
for streamlined profiling and reporting required to en-
able such routine clinical use in Switzerland.
Possible extensions of the SwissMTB workflow include
the integration of other molecular profiling technologies,
such as proteomics and single cell sequencing [99, 100].
Proteomic analysis would provide information on the
translated proteins in the tumor, thereby verifying vari-
ants identified on the genomic and transcriptomic level
and additionally detecting post-translational modifica-
tions. Post-translational modifications, such as phos-
phorylation or histone modifications, have been shown
to play a critical role in the development of a variety of
cancer types [101, 102] and in drug resistance develop-
ment. Their analysis would thus open a new window for
therapy possibilities [103]. Single-cell sequencing pro-
vides more detailed information on the genetic makeup
of the whole tumor tissue and its heterogeneous sub-
clones [100, 104]. Currently, treatments target actionable
variants that might be present in the majority, but not
all tumor cells. Cells without the variant can survive and
over time the tumor regrows. Single-cell sequencing
could inform on treatments necessary to target all sub-
clones of the tumor.
With declining sequencing costs, high coverage WGS
will become feasible not only for research, but also in
the clinics. This will enable the analysis of larger struc-
tural variants and eventually eliminate the need for WES
or panel sequencing. Already today, for instance the
100,000 genomes project in the UK performs WGS of
each sample at depths sufficient for variant calling [105].
In Swiss clinics currently panel sequencing is the stand-
ard diagnostic high-throughput technique as it is the
least cost- and analysis-intensive, and covered by health
insurances. However, decreasing costs for WES and
WGS will enable reimbursement also for these tech-
niques and shift the focus in routine diagnostics from
panel sequencing to whole exome and ultimately whole
genome analysis. Simultaneously, molecular diagnostics
based on high-throughput techniques will become the
tool of choice also for early diagnostics, not only to find
last therapy options for patients that have progressed on
all standard treatments. Applying comprehensive mo-
lecular cancer diagnostics already at the clinical entry
point also has benefits for patients with unknown pri-
mary tumor. The genetic makeup of the the tumor can
predict the tumor type, which improves the choice of
suitable therapies [106].
One of the greatest challenges in the SwissMTB is the
prioritization and clinical interpretation of genomic ab-
errations. This task is not yet fully automated and re-
quires manual inspection of sometimes large numbers of
drug-target combinations. Given the aspired short turn-
around time, further work is needed to automate the lit-
erature search for prioritization of targetable variants.
Here, one possible approach is the integration of text
mining methods to pre-filter variants with respect to
their importance and occurrence in the literature. Redu-
cing the list of possible targets to only promising ones
will greatly reduce the time and effort necessary to for-
mulate a concise clinical report.
In addition to these technical developments, also the
management and communication within the SwissMTB is
a constant learning process. Bridging the gap between
clinic and research and making the application of cutting
edge technologies feasible for clinical use requires that ex-
perts from both clinical and bioinformatics world come
together and discuss their needs for sufficient sample ana-
lysis. This involves the required analysis types and results,
as well as the way findings are reported. Consequently,
our clinical reports have evolved over time and will prob-
ably continue to evolve, based both on new technologies
and on feedback from the treating clinician regarding the
interpretability of analysis results. This iterative integra-
tion of new technologies and feedback into SwissMTB will
also introduce new challenges. Various sources of infor-
mation need to be summarized and presented in a concise
and easily interpretable report to be useful for discussion
in a tumor board. In the near future, the increasing num-
ber of profiling sources will require an interactive report
rather than the traditional pdf document to prioritize in-
formation, to allow focussing on the most promising, and
to access details on demand [64].
Because our workflow exclusively proposes therapies
by summarizing the evidence seen in the genomic and
transcriptomic landscape of the tumor, it is a new diag-
nostic tool for the clinician. Therefore, there is no need
for a research-related patient consent. However, using
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such a consent form (as is common practice in Swiss
hospitals) has the benefit to ensure that potential future
research projects can access these data. For instance,
with a growing number of sequenced patients a new
valuable resource to interpret results develops. Given the
appropriate consent, variants found in a certain tumor
type, as well as chosen therapies and their outcomes,
can form a resource which facilitates and improves ther-
apy recommendations for new patients. This was for in-
stance shown for acute myeloid leukemia in [107].
Naturally, also here the feedback from clinicians is es-
sential, and data has to be handled carefully in order to
ensure patient privacy.
Finally, approaching cancer therapy from a molecular
perspective demands a new design for clinical trials. In
recent years, so called basket trials emerged that stratify
patients not by their disease but rather based on their
genetic variants [69, 108]. These trials will be invaluable
to assess the actual therapy potential of specific action-
able variants across different cancer types. In addition,
as was for instance shown in [109], they can serve to
identify new molecular targets and thus broaden our un-
derstanding of tumor development and therapy.
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